Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society

被引：6

作者：

Collongues, Nicolas ^{[1
,2
,3
,4
]}

Durand-Dubief, Francoise ^{[5
]}

Lebrun-Frenay, Christine ^{[6
,7
]}

Audoin, Bertrand ^{[8
]}

Ayrignac, Xavier ^{[9
,10
,11
]}

Bensa, Caroline ^{[12
]}

Bigaut, Kevin ^{[1
,3
]}

Bourre, Bertrand ^{[13
]}

Carra-Dalliere, Clarisse ^{[9
]}

Ciron, Jonathan ^{[14
,15
]}

Defer, Gilles ^{[16
]}

Kwiatkowski, Arnaud ^{[17
]}

Leray, Emmanuelle ^{[18
]}

Maillart, Elisabeth ^{[19
]}

Marignier, Romain ^{[5
]}

Mathey, Guillaume ^{[20
]}

Morel, Nathalie ^{[21
]}

Thouvenot, Eric ^{[22
,23
]}

Zephir, Helene ^{[24
]}

Boucher, Julie ^{[25
]}

Boutiere, Clemence ^{[26
]}

Branger, Pierre ^{[27
]}

Da Silva, Angelique ^{[28
]}

Demortiere, Sarah ^{[8
]}

Guillaume, Maxime ^{[13
]}

Hebant, Benjamin ^{[13
]}

Januel, Edouard ^{[29
,30
,31
]}

Kerbrat, Anne ^{[32
,33
]}

Manchon, Eric ^{[34
]}

Moisset, Xavier ^{[35
]}

Montcuquet, Alexis ^{[36
]}

Pierret, Chloe ^{[18
]}

Pique, Julie ^{[5
]}

Poupart, Julien ^{[37
,38
]}

Prunis, Chloe ^{[20
]}

Roux, Thomas ^{[39
,40
]}

Schmitt, Perrine ^{[22
]}

Androdias, Geraldine ^{[41
,42
]}

Cohen, Mikael ^{[6
,7
]}

机构：

[1] Univ Hosp Strasbourg, Dept Neurol, F-67091 Strasbourg, France

[2] INSERM, Ctr Clin Invest, U1434, Strasbourg, France

[3] INSERM, Biopathol Myelin Neuroprotect & Therapeut Strateg, U1119, Strasbourg, France

[4] Strasbourg Univ, Dept Pharmacol Addictol Toxicol & Therapeut, Strasbourg, France

[5] Hop Neurol & Neurochirurg P Wertheimer, Serv Sclerose Plaques Pathol Myeline & Neuroinfla, Bron, France

[6] CHU Nice, Dept Neurol, Nice, France

[7] Univ Cote dAzur, URRIS UMR2CA, Nice, France

[8] Aix Marseille Univ, AP HM, CRMBM, Dept Neurol, Marseille, France

[9] Montpellier Univ Hosp, Dept Neurol, Montpellier, France

[10] Univ Montpellier, Montpellier, France

[11] INM, INSERM, Montpellier, France

[12] Hop Fdn Adolphe de Rothschild, Dept Neurol, Paris, France

[13] CHU Rouen, Dept Neurol, Rouen, France

[14] CHU Toulouse, Dept Neurol, CRC SEP, Toulouse, France

[15] Univ Toulouse III, Infinity, INSERM, CNRS,UMR 5051,UMR 1291, Toulouse, France

[16] Caen Univ Hosp, Dept Neurol, Caen, France

[17] Lille Catholic Univ, Lille Catholic Hosp, Dept Neurol, Lille, France

[18] Univ Rennes, EHESP, CNRS, INSERM,ARENES,UMR 6051,RSMS,U1309, Rennes, France

[19] Hop La Pitie Salpetriere, Dept Neurol, Paris, France

[20] Nancy Univ Hosp, Dept Neurol, Nancy, France

[21] Ctr Hosp Annecy Genevois, Serv Neurol, Epagny Metz Tessy, France

[22] CHU Nimes, Serv Neurol, Nimes, France

[23] Univ Montpellier, Inst Genom Fonct, CNRS, INSERM, Montpellier, France

[24] Univ Lille, CHU Lille, INSERM, U1172, Lille, France

[25] CHU Lille, Dept Neurol, Lille, France

[26] Univ Hosp Marseille, Dept Neurol, Marseille, France

[27] CHU Caen Normandie, Serv Neurol, Caen, France

[28] Inst Normand Sein, Ctr Francois Baclesse, Breast Canc Unit, Caen, France

[29] Sorbonne Univ, Paris, France

[30] Hop La Pitie Salpetriere, Inst Pierre Louis Epidemiol & Sante Publ, AP HP, Dept Sante Publ, Paris, France

[31] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Paris, France

[32] CHU Rennes, Serv Neurol, Rennes, France

[33] INRIA, EMPENN, INSERM, U1228, Rennes, France

[34] Ctr Hosp Gonesse, Serv Neurol, Gonesse, France

[35] Univ Clermont Auvergne, CHU Clermont Ferrand, INSERM, Neurodol, Clermont Ferrand, France

[36] CHU Bordeaux, Dept Neurol, Bordeaux, France

[37] Univ Lille, CHU Lille, Dept Neurol, Lille, France

[38] Univ Lille, CHU Lille, Lille Inflammat Res Int Ctr, INSERM,U995,LIRIC, Lille, France

[39] Hop La Pitie Salpetriere, Serv Neurol, Paris, France

[40] CRC SEP Paris, Ctr Malad Inflammatoires Rares Cerveau & Moelle E, Paris, France

[41] Hop Neurol & Neurochirurg P Wertheimer, Serv Neurol, Serv Sclerose Plaques Pathol Myeline & Neuroinfla, Bron, France

[42] Clin Sauvegarde Ramsay Sante, Lyon, France

来源：

MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 07期

关键词：

Multiple sclerosis; cancer; disease-modifying treatments; checkpoint inhibitors; immunotherapy; IMMUNE CHECKPOINT INHIBITORS; CENTRAL-NERVOUS-SYSTEM; STEM-CELL TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; MELANOMA COMPLICATING TREATMENT; DISEASE-MODIFYING THERAPIES; MYCOPHENOLATE-MOFETIL; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; CONTROLLED PHASE-3;

D O I：

10.1177/13524585231223880

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Epidemiological data reveal that 45% of persons with multiple sclerosis (PwMS) in France are more than 50 years. This population more than 50 is more susceptible to cancer, and this risk may be increased by frequent use of immunosuppressive drugs. Consequently, concerns have arisen about the potential increased risk of cancer in PwMS and how patients should be screened and managed in terms of cancer risk.Objective: To develop evidence-based recommendations to manage the coexistence of cancer and multiple sclerosis (MS).Methods: The French Group for Recommendations in MS collected articles from PubMed and university databases covering the period January 1975 through June 2022. The RAND/UCLA method was employed to achieve formal consensus. MS experts comprehensively reviewed the full-text articles and developed the initial recommendations. A group of multidisciplinary health care specialists then validated the final proposal.Results: Five key questions were addressed, encompassing various topics such as cancer screening before or after initiating a disease-modifying therapy (DMT), appropriate management of MS in the context of cancer, recommended follow-up for cancer in patients receiving a DMT, and the potential reintroduction of a DMT after initial cancer treatment. A strong consensus was reached for all 31 recommendations.Conclusion: These recommendations propose a strategic approach to managing cancer risk in PwMS.

引用

页码：899 / 924

页数：26

共 208 条

[1]

Abdel-Wahab N, 2018, ANN INTERN MED, V169, P133, DOI 10.7326/L18-0209

[2] Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments [J].